Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RASolve 301
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
1 other identifier
interventional
590
19 countries
152
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started May 2025
Longer than P75 for phase_3
152 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 10, 2025
CompletedFirst Posted
Study publicly available on registry
March 18, 2025
CompletedStudy Start
First participant enrolled
May 6, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2030
August 6, 2026
July 1, 2026
2.6 years
March 10, 2025
August 4, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C)
PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by BICR.
Up to approximately 4 years
Overall survival (OS) in the RAS G12X-C population
OS is defined as the time from randomization until death from any cause.
Up to approximately 4 years
Secondary Outcomes (11)
PFS in the RAS (MUT) population per BICR
Up to approximately 4 years
OS in the RAS (MUT) population
up to approximately 4 years
Objective response per BICR in the RAS (G12X-C) and RAS (MUT) populations
Up to approximately 4 years
PFS per Investigator in the RAS (G12X-C) and RAS (MUT) populations
Up to approximately 4 years
Objective response per Investigator in the RAS (G12X-C) and RAS (MUT) populations
Up to approximately 4 years
- +6 more secondary outcomes
Study Arms (2)
daraxonrasib
EXPERIMENTALstudy drug
docetaxel
ACTIVE COMPARATORPatients randomized to the comparator control arm will receive docetaxel as the standard of care therapy.
Interventions
Eligibility Criteria
You may qualify if:
- At least 18 years old and has provided informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Pathologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy.
- Measurable disease per RECIST v1.1.
- Adequate organ function (bone marrow, liver, kidney, coagulation).
- One to two prior lines of therapy including an anti-PD-1/anti-PD(L)-1 agent and platinum-based chemotherapy.
- Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61).
- Able to take oral medications.
You may not qualify if:
- Prior therapy with direct RAS-targeted therapy or docetaxel.
- Untreated central nervous system (CNS) metastases.
- Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function).
- Ongoing anticancer therapy.
- Pregnant or breastfeeding.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (152)
Alabama Oncology
Birmingham, Alabama, 35243, United States
MemorialCare Long Beach Medical Center
Long Beach, California, 90806, United States
Yale University, Smillow Cancer Center
New Haven, Connecticut, 06519, United States
Florida Cancer Specialists & Research Institute - South
Fort Myers, Florida, 33901, United States
BRCR Global
Plantation, Florida, 33322, United States
Cancer Care Centers of Breevard
Rockledge, Florida, 32955, United States
Florida Cancer Specialists & Research Institute - North
St. Petersburg, Florida, 33705, United States
Cleveland Clinic Martin North
Stuart, Florida, 34994, United States
Florida Cancer Specialists & Research Institute - East
West Palm Beach, Florida, 33401, United States
University Cancer and Blood Center
Athens, Georgia, 30607, United States
Piedmont Healthcare, Inc
Atlanta, Georgia, 30318, United States
Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Center for Care and Discovery
Chicago, Illinois, 60637, United States
University of Iowa Health Care Cancer Services Quad Cities
Bettendorf, Iowa, 52722, United States
University of Iowa Hospitals & Clinics
Iowa City, Iowa, 52242, United States
University of Iowa Health Care, Mission Cancer + Blood
Waukee, Iowa, 50263, United States
The University of Kansas Cancer Center
Westwood, Kansas, 66205, United States
Johns Hopkins University of Medicine
Baltimore, Maryland, 21224, United States
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Henry Ford Health
Detroit, Michigan, 48202, United States
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri, 63110, United States
St. Vincent Frontier Cancer Center
Billings, Montana, 59102, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
John Theurer Cancer Center at Hackensack UMC
Hackensack, New Jersey, 07601, United States
Morristown Medical Center (MMCORC)
Morristown, New Jersey, 07960, United States
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Montefiore Medical Center
The Bronx, New York, 10461, United States
UNC Lineberger Comprehensive Cancer Center at University of North Carolina
Chapel Hill, North Carolina, 27599, United States
TriHealth Cancer & Blood Institute Research
Cincinnati, Ohio, 45220, United States
Taylor Cancer Research Center
Maumee, Ohio, 43537, United States
Oncology Associates of Oregon PC
Eugene, Oregon, 97401, United States
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033, United States
Avera Saint Luke's Hospital
Aberdeen, South Dakota, 57401, United States
Avera Cancer Institute
Sioux Falls, South Dakota, 57105, United States
SCRI Oncology Partners - Tennessee
Nashville, Tennessee, 37203, United States
Texas Oncology - South Austin
Austin, Texas, 78745, United States
Texas Oncology Dallas
Dallas, Texas, 75251, United States
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Texas Oncology - Gulf Coast
The Woodlands, Texas, 77380, United States
Utah Cancer Specialists
Salt Lake City, Utah, 84106, United States
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
Blacktown Medical Oncology Research, Blacktown Hospital
Blacktown, New South Wales, 2148, Australia
Blacktown Medical Oncology Research
Blacktown, New South Wales, 2148, Australia
Chris O'Brien Lifehouse
Camperdown, New South Wales, 2050, Australia
St. George Private Hospital Clinical Trials Unit
Kogarah, New South Wales, 2217, Australia
Calvary Mater Newcastle
Waratah, New South Wales, 2298, Australia
Mater Misericordiae Limited
South Brisbane, Queensland, 4101, Australia
Alfred House
Melbourne, Victoria, 3004, Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, 6009, Australia
Institut Jules Bordet
Anderlecht, Belgium, 1070, Belgium
Grand Hôpital de Charleroi - Les Viviers
Gilly, 6060, Belgium
AZ Groeninge
Kortrijk, 8500, Belgium
UZ Leuven-Campus Gasthuisberg
Leuven, 3000, Belgium
AZ Delta
Roeselare, 8800, Belgium
CHU Strasbourg - Nouvel Hôpital Civil
Strasbourg, Bas Rhin, 67091, France
Hopital Nord - CHU Marseille
Marseille, Bouches-du-Rhône, 13915, France
Institut régional du Cancer de Montpellier
Montpellier, Herault, 34298, France
CHU Rennes Hôpital Pontchaillou
Rennes, Ille et Vilaine, 35033, France
CHU de Grenoble - Hôpital Albert Michallon
La Tronche, Isere, 38700, France
CHU Nantes - Hôpital Guillaume et René Laënnec
Saint-Herblain, Loire Atlantique, 44805, France
Institut de Cancerologie de l Ouest
Saint-Herblain, Loire Atlantique, 44805, France
Centre Leon Berard
Léon, Lyon, 69008, France
Hopital Albert Calmette - CHU Lille
Lille, Nord, 59037, France
Hôpital Bichat - Claude Bernard
Paris, Paris, 75018, France
Hopital Louis Pradel
Bron, Rhone, 69677, France
Centre Hospitalier Intercommunal de Créteil
Créteil, Val de Marne, 94000, France
Institut Gustave Roussy
Vaillant, Villejuif, 94800, France
CHU Brest - Hôpital Morvan
Brest, 29200, France
Institut Bergonie
Gironde, 33076, France
CHU de Toulouse - Hopital Larrey
Toulouse, 31059, France
LKI Lungenfachklinik Immenhausen
Immenhausen, Hesse, 34376, Germany
Universitaetsklinikum Essen
Essen, North Rhine-Westphalia, 45147, Germany
Universitaetsklinikum Carl Gustav Carus TU Dresden
Dresden, Saxony, 01307, Germany
Thoraxklinik Heidelberg gGmbH
Baden, Wuerttemberg, 69469, Germany
Klinikum Esslingen GmbH
Baden, 73730, Germany
Evangelische Lungenklinik Berlin
Berlin, 13125, Germany
Hong Kong United Oncology Centre
Hong Kong, Hong Kong
Queen Mary Hospital
Hong Kong, Hong Kong
The Chinese University of Hong Kong
Shatin, 00000, Hong Kong
Cork Univeristy Hospital
Cork, Cork, T12 DC4A, Ireland
Mater Private Hospital
Dublin, Dublin, 7, Ireland
University Hospital Limerick
Cork, Limerick, V94 F858, Ireland
Tallaght University Hospital
Dublin, 24, Ireland
Beaumont Hospital Cancer Clinical
Dublin, D09 V2N0, Ireland
Galway University Hospital
Galway, H91 YR71, Ireland
IEO Istituto Europeo di Oncologia
Milan, Milano, 20141, Italy
Azienda Socio Sanitaria Territoriale Niguarda
Milan, Milano, 21206, Italy
Istituto Clinico Humanitas
Rossano, Milano, 20089, Italy
Fondazione IRCCS San Gerardo dei Tintori
Monza, Milan, 20900, Italy
Istituto Nazionale Tumori Fondazione G. Pascale
Naples, Napoli, 80131, Italy
Azienda Ospedaliero Universitaria Pisana (Presidio di Cisanello)
Pisa, Pisa, 56124, Italy
Istituto Nazionale dei Tumori Regina Elena IRCCS
Roma, Roma, 00144, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, 00168, Italy
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, 464-8681, Japan
Fujita Health University Hospital
Toyoake-shi, Aichi-ken, 470-1192, Japan
National Cancer Center Hospital East
Kashiwa-shi, Chiba, 277-8577, Japan
NHO Himeji Medical Center
Matsuyama, Ehime, 791-0280, Japan
NHO Shikoku Cancer Center
Matsuyama, Ehime, 791-0280, Japan
National Hospital Organization Hokkaido Cancer Center
Sapporo, Hokkaido, 003-0804, Japan
Hyogo Cancer Center
Akashi, Hyōgo, 673-8558, Japan
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, 920-8641, Japan
Kanagawa Cancer Center
Yokohama, Kanagawa, 241-8515, Japan
Tohoku University Hospital
Sendai, Miyagi, 980-8574, Japan
Sendai Kousei Hospital
Sendai, Miyagi, 981-0914, Japan
Nara Medical University Hospital
Kashihara-shi, Nara, 634-8522, Japan
Niigata Cancer Center
Niigata, Niigata, 951-8566, Japan
Kansai Medical University Hospital
Hirakata-shi, Osaka, 573-1191, Japan
Kindai University Hospital
Osakasayama-shi, Osaka, 589-8511, Japan
Shizuoka Cancer Center
Nagaizumi-chō, Shizuoka, 411-8777, Japan
National Cancer Center Hospital
Chuo Ku, Tokyo, 104-0045, Japan
Cancer Institute Hospital of JFCR
Koto-Ku, Tokyo, 135-8550, Japan
Wakayama Medical University Hospital
Wakayama, Wakayama, 641-8510, Japan
Amsterdam UMC, Locatie VUMC
Amsterdam, Netherlands, 1081BT, Netherlands
Erasmus Medisch Centrum
Rotterdam, Netherlands, 3015AA, Netherlands
Antoni van Leeuwenhoek
Amsterdam, 1066 CX, Netherlands
Maastricht University Medical Center P. Debyelaan 25
Maastricht, 6229, Netherlands
Radboudumc
Nijmegen, 6525 GA, Netherlands
Auckland City Hospital - Cancer and Blood Research
Grafton, Auckland, 1023, New Zealand
Klinika Onkologii I Radioterapii UCK
Gdansk, 80-214, Poland
INSTYTUT GENETYKI I IMMMUNOLOGII GENIM sp. z o.o.
Lublin, 29-609, Poland
Med-Polonia Sp. z o.o.
Poznan, 60-693, Poland
Aidport Sp. z o.o.
Skorzewo, 60-185, Poland
Pan American Center for Oncology Trials
San Juan, Puerto Rico, 00909, Puerto Rico
National University Hospital
Singapore, Singapore, 119074, Singapore
National Cancer Centre Singapore
Singapore, 168583, Singapore
Icon Cancer Centre
Singapore, 574623, Singapore
Ajou University Hospital
Gyeonggi-do, Suwon-si, 16499, South Korea
Chungbuk National University Hospital
Cheongju-si, 28644, South Korea
Chonnam National University Hwasun Hospital
Hwasun, 58128, South Korea
Korea University Anam Hospital
Seoul, 02841, South Korea
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
Samsung Medical Center
Seoul, 06351, South Korea
Complejo Hospitalario Universitario A Coruña
A Coruña, A Coruña, 15006, Spain
Hospital Universitari Dexeus
Barcelona, Barcelona, 08028, Spain
Hospital Universitario La Paz
Fuencarral-El Pardo, Madrid, 28046, Spain
Hospital Universitario HM Madrid Sanchinarro
Madrid, Madrid, 28050, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, 08041, Spain
Universitätsspital Basel
Basel, 4031, Switzerland
HFR Fribourg/Kantonsspital Fribourg
Fribourg, 1708, Switzerland
Kantonsspital St. Gallen
Sankt Gallen, 9000, Switzerland
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung, Taiwan, 100, Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan, 704, Taiwan
National Taiwan University Hospital
Taipei, Taiwan, 10002, Taiwan
Taipei Medical University Hospital
Taipei, 110, Taiwan
Chang Gung Medical Foundation Linkou
Taoyuan, 333, Taiwan
Royal Marsden Hospital-London
London, Greater London, SW3 6JJ, United Kingdom
The Clatterbridge Cancer Centre
Liverpool, Merseyside, L7 8YA, United Kingdom
Royal Marsden Hospital-Sutton
Sutton, Surrey, SM2 5PT, United Kingdom
Royal Free Hospital
London, W3 2QG, United Kingdom
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Masking Details
- The central reader of the tumor scans will be masked to the patients' treatment arm.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 10, 2025
First Posted
March 18, 2025
Study Start
May 6, 2025
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2030
Last Updated
August 6, 2026
Record last verified: 2026-07